Structures by: Childs S. L.
Total: 52
C22H27NO2,C8H8O3
C22H27NO2,C8H8O3
Molecular pharmaceutics (2013) 10, 8 3112-3127
a=6.6170(3)Å b=19.6403(10)Å c=20.1853(9)Å
α=90° β=90° γ=90°
Theophylline:salicylic acid cocrystal (1:1)
C7H9N4O2,C7H6O3
Molecular Pharmaceutics (2007) 4, 3 323
a=6.9183(3)Å b=25.9086(10)Å c=7.9749(4)Å
α=90.00° β=104.754(3)° γ=90.00°
Niflumic acid:maleic acid salt (1:1)
C13H10N2O2F3,C4H3O4
Molecular Pharmaceutics (2007) 4, 3 323
a=8.1434(5)Å b=20.7559(11)Å c=10.6511(7)Å
α=90.00° β=110.276(3)° γ=90.00°
Theophylline:4-hydroxybenzoic acid cocrystal (1:1)
C7H8N4O2,C7H6O3
Molecular Pharmaceutics (2007) 4, 3 323
a=7.1201(18)Å b=7.928(2)Å c=24.763(6)Å
α=90.00° β=91.660(7)° γ=90.00°
Theophylline:1-hydroxy-2-naphthoic acid cocrystal (1:1)
C7H8N4O2,C11H8O3
Molecular Pharmaceutics (2007) 4, 3 323
a=11.814(3)Å b=31.707(8)Å c=8.920(2)Å
α=90.00° β=98.072(7)° γ=90.00°
Theophylline:sorbic acid cocrystal (1:1)
C7H8N4O2,C6H8O2
Molecular Pharmaceutics (2007) 4, 3 323
a=8.7478(2)Å b=6.53610(10)Å c=12.5842(2)Å
α=90.00° β=107.2960(10)° γ=90.00°
Theophylline:acetaminophen cocrystal (1:1)
C7H8N4O2,C8H9NO2
Molecular Pharmaceutics (2007) 4, 3 323
a=8.7337(2)Å b=15.3838(3)Å c=11.5271(3)Å
α=90.00° β=99.256(2)° γ=90.00°
Anhydrous aminophylline
C7H7N4O2,0.5(C2H10N2)
Molecular Pharmaceutics (2007) 4, 3 323
a=8.7804(5)Å b=6.5989(4)Å c=16.0041(10)Å
α=90.00° β=102.292(4)° γ=90.00°
Aminophylline hydrate
2(C7H7N4O2),0.5(C2H10N2),0.5(C2H10N2),H2O
Molecular Pharmaceutics (2007) 4, 3 323
a=8.3936(7)Å b=10.2277(6)Å c=11.8295(6)Å
α=78.839(3)° β=77.795(4)° γ=81.075(4)°
C24H22N4O11
C24H22N4O11
CrystEngComm (2012) 14, 15 5078
a=7.2120(6)Å b=27.7094(17)Å c=12.0909(9)Å
α=90.00° β=91.789(8)° γ=90.00°
Nitrofurantoin:citric acid cocrystal
C8H6N4O5,C6H8O7
CrystEngComm (2012) 14, 15 5078
a=13.444(1)Å b=11.480(1)Å c=12.434(1)Å
α=90.000° β=113.736(1)° γ=90.000°
N-(4-methoxyphenyl)-N'-(piperidino)thiourea
C13H18N2OS
Green Chemistry (2012) 14, 9 2462
a=10.4930(2)Å b=14.6391(4)Å c=9.0779(2)Å
α=90.00° β=113.0210(10)° γ=90.00°
5-Chloro-2(3H)-benzoxazolone 2,4-dihydroxybenzoic acid
C7H4ClNO2,C7H6O4
CrystEngComm (2007) 9, 5 364
a=6.7431(5)Å b=8.0503(6)Å c=13.8001(10)Å
α=77.722(3)° β=88.476(2)° γ=66.354(2)°
N-phenyl-N'-(thiomorpholino)thiourea
C11H14N2S2
Green Chemistry (2012) 14, 9 2462
a=11.5813(3)Å b=9.3856(3)Å c=10.8926(4)Å
α=90.00° β=101.21(3)° γ=90.00°
N,N'-bis(4-fluorophenyl)thiourea
C13H10F2N2S
Green Chemistry (2012) 14, 9 2462
a=8.3457(1)Å b=26.4224(2)Å c=5.3071(6)Å
α=90.00° β=90.00° γ=90.00°
N-(4-nitrophenyl)-N'-(morpholino)thiourea
C11H13N3O3S
Green Chemistry (2012) 14, 9 2462
a=10.2252(2)Å b=10.5172(3)Å c=11.1949(2)Å
α=90.00° β=90.788(2)° γ=90.00°
N-(4-nitrophenyl)-N'-(morpholino)thiourea
C11H13N3O3S1
Green Chemistry (2012) 14, 9 2462
a=21.2213(10)Å b=8.0908(4)Å c=28.6471(15)Å
α=90.00° β=90.00° γ=90.00°
C14H14N2O1S1
C14H14N2O1S1
Green Chemistry (2012) 14, 9 2462
a=28.4936(24)Å b=5.55569(33)Å c=8.14303(38)Å
α=90° β=90.7479(43)° γ=90°
C14H13N3O2S1
C14H13N3O2S1
Green Chemistry (2012) 14, 9 2462
a=14.50439(92)Å b=13.62318(93)Å c=7.14076(26)Å
α=90° β=90° γ=90°
C15H16N2S1
C15H16N2S1
Green Chemistry (2012) 14, 9 2462
a=12.67213(25)Å b=9.79731(27)Å c=12.10093(31)Å
α=90° β=115.2231(14)° γ=90°
Ezetimibe
C24H21F2NO3
CrystEngComm (2014) 16, 38 8984
a=5.9510(19)Å b=15.899(5)Å c=21.400(16)Å
α=90° β=90° γ=90°
Ezetimibe-Imidazole
C24H21F2NO3,C3H4N2
CrystEngComm (2014) 16, 38 8984
a=5.8320(2)Å b=15.7520(5)Å c=25.6730(13)Å
α=90° β=90° γ=90°
Ezetimibe-Formamide
C24H21F2N1O3,C1H3N1O1
CrystEngComm (2014) 16, 38 8984
a=6.1400(2)Å b=17.0770(7)Å c=21.3500(12)Å
α=90° β=90° γ=90°
Fluoxetine hydrochloride:fumaric acid cocrystal (2:1)
2(C17H19F3NO1Cl1),C4H4O4
Journal of the American Chemical Society (2004) 126, 13335-13342
a=26.6914(8)Å b=7.1807(3)Å c=20.6546(7)Å
α=90.00° β=90.00° γ=90.00°
Fluoxetine hydrochloride:benzoic acid cocrystal (1:1)
(C17H19F3NO1,Cl1),C7H6O2
Journal of the American Chemical Society (2004) 126, 13335-13342
a=14.806(5)Å b=13.179(4)Å c=24.417(7)Å
α=90.00° β=97.738(13)° γ=90.00°
Fluoxetine hydrochloride:succinic acid cocrystal (2:1)
2(C17H19F3NO1Cl1),C4H6O4
Journal of the American Chemical Society (2004) 126, 13335-13342
a=26.620(2)Å b=7.2147(7)Å c=20.8315(19)Å
α=90.00° β=90.00° γ=90.00°
Piroxicam:1-hydroxy-2-naphthoic acid cocrystal (1:1)
C15H13N3O4S,C11H8O3
Crystal Growth & Design (2007) 7, 7 1291
a=6.9743(6)Å b=12.3558(9)Å c=14.9892(14)Å
α=114.045(6)° β=92.672(7)° γ=95.105(6)°
Piroxicam:caprylic acid cocrystal (1:1)
C15H13N3O4S,C8H16O2
Crystal Growth & Design (2007) 7, 7 1291
a=8.4286(6)Å b=9.7241(6)Å c=15.2060(9)Å
α=94.674(3)° β=105.723(3)° γ=97.953(3)°
Piroxicam:4-hydroxybenzoic acid cocrystal, Form 1 (1:1)
C15H13N3O4S,C7H6O3
Crystal Growth & Design (2007) 7, 7 1291
a=9.3201(10)Å b=16.4366(17)Å c=14.2134(15)Å
α=90.00° β=100.561(2)° γ=90.00°
Piroxicam:succinic acid cocrystal (2:1)
C15H13N3O4S,0.5(C4H6O4)
Crystal Growth & Design (2007) 7, 7 1291
a=7.7069(2)Å b=8.4282(2)Å c=14.4344(3)Å
α=79.638(1)° β=74.987(1)° γ=72.616(1)°
Piroxicam:malonic acid
C15H13N3O4S,C8H16O2
Crystal Growth & Design (2007) 7, 7 1291
a=15.692(8)Å b=16.195(7)Å c=6.999(3)Å
α=90.00° β=101.720(11)° γ=90.00°
Piroxicam:4-hydroxybenzoic acid cocrystal, Form 2 (1:1)
C15H13N3O4S,C7H6O3
Crystal Growth & Design (2007) 7, 7 1291
a=7.4086(10)Å b=10.9004(15)Å c=12.9268(17)Å
α=95.965(3)° β=100.576(3)° γ=96.858(2)°
Piroxicam:benzoic acid cocrystal (1:1)
C15H13N3O4S,C7H6O2
Crystal Growth & Design (2007) 7, 7 1291
a=10.5790(8)Å b=21.0495(16)Å c=9.2413(8)Å
α=90.00° β=95.152(4)° γ=90.00°
Piroxicam:fumaric acid cocrystal (4:1)
2[C15H13N3O4S],0.5[C4H4O4]
Crystal Growth & Design (2007) 7, 7 1291
a=8.7433(12)Å b=10.9557(15)Å c=16.633(2)Å
α=86.335(3)° β=89.030(2)° γ=84.809(3)°
Piroxicam:p-dioxane solvate (4:1)
C15H13N3O4S,0.25(C4H8O2)
Crystal Growth & Design (2007) 7, 7 1291
a=10.5355(13)Å b=12.7289(14)Å c=13.1794(14)Å
α=102.048(6)° β=99.758(7)° γ=109.836(8)°
Metformin HCl form I
C4H12ClN5
Crystal Growth & Design (2004) 4, 3 441
a=7.9231(12)Å b=13.894(2)Å c=7.9231(12)Å
α=90.00° β=114.48° γ=90.00°
Metformin HCl form II
C4H12ClN5
Crystal Growth & Design (2004) 4, 3 441
a=7.6261(7)Å b=6.1684(6)Å c=18.1508(16)Å
α=90.00° β=99.447(2)° γ=90.00°
Nabumatone Form I
C15H16O2
Crystal Growth & Design (2002) 2, 6 505
a=21.8603(5)Å b=5.33350(10)Å c=22.2337(6)Å
α=90.00° β=111.9288(11)° γ=90.00°
Nabumatone Form II
C15H16O2
Crystal Growth & Design (2002) 2, 6 505
a=26.9485(4)Å b=5.8773(4)Å c=7.8960(18)Å
α=90.00° β=91.767(3)° γ=90.00°
Carbamazepine:acidpic acid cocrystal (2:1)
C18H17N2O3
Crystal Growth & Design (2009) 9, 4 1869
a=7.3375(8)Å b=14.7716(17)Å c=15.8886(18)Å
α=69.376(8)° β=84.178(9)° γ=88.266(9)°
Carbamazepine:4-hydroxybenzoic acid cocrystal, form C (1:1)
C15H12N2O,C7H6O3
Crystal Growth & Design (2009) 9, 4 1869
a=13.3059(9)Å b=6.6658(4)Å c=20.7091(14)Å
α=90.00° β=91.0140(10)° γ=90.00°
Carbamazepine host structure with 4-hydroxybenzoic acid removed
C15H12N2O
Crystal Growth & Design (2009) 9, 4 1869
a=20.4438(9)Å b=5.1527(2)Å c=26.5197(12)Å
α=90.00° β=95.264(2)° γ=90.00°
Carbamazepine:4-hydroxybenzoic acid cocrystal, form A (1:1)
C22H18N2O4
Crystal Growth & Design (2009) 9, 4 1869
a=7.0994(3)Å b=12.7087(6)Å c=20.1105(9)Å
α=90.00° β=91.870(2)° γ=90.00°
Carbamazepine:glutaric acid cocrystal (1:1)
C20H20N2O5
Crystal Growth & Design (2009) 9, 4 1869
a=18.5619(10)Å b=5.1201(3)Å c=19.4588(9)Å
α=90.00° β=106.839(3)° γ=90.00°
Carbamazepine host structure with malonic acid removed
C15H12N2O
Crystal Growth & Design (2009) 9, 4 1869
a=10.3327(15)Å b=26.611(5)Å c=5.0875(9)Å
α=90.00° β=104.258(9)° γ=90.00°
Carbamazepine:salicylic acid cocrystal (1:1)
C22H18N2O4
Crystal Growth & Design (2009) 9, 4 1869
a=5.1064(6)Å b=19.783(2)Å c=18.328(2)Å
α=90.00° β=97.903(7)° γ=90.00°
Carbamazepine host structure with DL-tartaric acid removed
C15H12N2O
Crystal Growth & Design (2009) 9, 4 1869
a=10.3006(9)Å b=26.972(2)Å c=5.0718(4)Å
α=90.00° β=104.235(6)° γ=90.00°
Carbamazepine:1-hydroxy-2-naphthoic acid cocrystal (1:1)
C26H20N2O4
Crystal Growth & Design (2009) 9, 4 1869
a=16.6411(13)Å b=5.0526(5)Å c=24.493(2)Å
α=90.00° β=99.062(6)° γ=90.00°
Carbamazepine host structure with maleic acid removed
C15H12N2O
Crystal Growth & Design (2009) 9, 4 1869
a=10.4207(14)Å b=26.168(4)Å c=5.2089(7)Å
α=90.00° β=104.346(9)° γ=90.00°
Carbamazepine host structure with oxalic acid removed
C15H12N2O
Crystal Growth & Design (2009) 9, 4 1869
a=10.330(14)Å b=26.24(3)Å c=5.110(6)Å
α=90.00° β=104.21(3)° γ=90.00°
Carbamazepine:(+)-camphoric acid cocrystal (1:1)
C25H28N2O5
Crystal Growth & Design (2009) 9, 4 1869
a=12.5885(6)Å b=13.1453(6)Å c=14.4820(7)Å
α=90.00° β=105.745(2)° γ=90.00°
Carbamazepine:benzoic acid cocrystal (1:1)
C22H18N2O3
Crystal Growth & Design (2009) 9, 4 1869
a=28.5185(18)Å b=5.1607(4)Å c=24.7363(15)Å
α=90.00° β=103.448(4)° γ=90.00°